BLT chart continues after this weeks trading to remain very bullish short, medium and longterm. The presentation by Alnylam Pharmaceuticals at the ASCO Meeting on Saturday June 4th re the full results of the ""Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. (Abstract #3025) presented by Andres Cervantes "" and the presentation by Silence Therapeutics on Monday June 6th "'First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors. (Abstract #3057) presented by Dirk Strumberg"" may be the catylist for a rerate of this stock and the sector it operates in. Lets see how we go, Goodluck .....................................................